Eiger BioPharmaceuticals Inc EIGR:OTCPK

*Data is delayed | Exchange | USD
Last | undefined
()
52 week range
0.00 - 0.00
Loading...
  • Open-
  • Day High-
  • Day Low-
  • Prev Close-
  • 52 Week High0.00
  • 52 Week High Date-
  • 52 Week Low0.00
  • 52 Week Low Date-

Key Stats

  • Market Cap-
  • Shares Out-
  • 10 Day Average Volume-
  • Dividend-
  • Dividend Yield-
  • Beta-
  • YTD % Change-

KEY STATS

  • Open-
  • Day High-
  • Day Low-
  • Prev Close-
  • 52 Week High0.00
  • 52 Week High Date-
  • 52 Week Low0.00
  • 52 Week Low Date-
  • Market Cap-
  • Shares Out-
  • 10 Day Average Volume-
  • Dividend-
  • Dividend Yield-
  • Beta-
  • YTD % Change-

RATIOS/PROFITABILITY

  • EPS (TTM)-
  • P/E (TTM)-
  • Fwd P/E (NTM)-
  • EBITDA (TTM)-
  • ROE (TTM)-
  • Revenue (TTM)-
  • Gross Margin (TTM)-
  • Net Margin (TTM)-
  • Debt To Equity (MRQ)-

EVENTS

  • Earnings Date-
  • Ex Div Date-
  • Div Amount-
  • Split Date-
  • Split Factor-

Latest On Eiger BioPharmaceuticals Inc

 

Content From Our Affiliates

Profile

MORE
Eiger BioPharmaceuticals, Inc. is a commercial-stage biopharmaceutical company focused on the development of therapies for hepatitis delta virus (HDV) and other serious diseases. Its HDV platform includes lonafarnib, an oral farnesylation inhibitor that targets a critical host process involved in viral replication. Its portfolio also includes avexitide, a well-characterized GLP-1 antagonist, as a targeted treatment for two metabolic diseases with high unmet medical needs. Its...
Thomas Dietz Ph.D.
Independent Chairman of the Board
David Apelian M.D., Ph.D.
Chief Executive Officer, Director
Address
2155 Park Blvd
Palo Alto, CA
94306-1543
United States